Novavax Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Novavax stock.
View analyst ratings for Novavax or view top-rated stocks.

8 brokerages have issued 12-month target prices for Novavax's shares. Their NVAX stock forecasts range from $35.00 to $209.00. On average, they predict Novavax's stock price to reach $164.00 in the next twelve months. This suggests a possible upside of 211.3% from the stock's current price.
View analysts' price targets for Novavax or view top-rated stocks among Wall Street analysts.

Novavax's stock was trading at $143.07 at the beginning of 2022. Since then, NVAX shares have decreased by 63.2% and is now trading at $52.68.
View the best growth stocks for 2022 here.

Novavax saw a increase in short interest in the month of June. As of June 15th, there was short interest totaling 15,730,000 shares, an increase of 30.0% from the May 31st total of 12,100,000 shares. Based on an average daily volume of 5,900,000 shares, the short-interest ratio is presently 2.7 days.
View Novavax's Short Interest.

Novavax is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Novavax.

Novavax, Inc. (NASDAQ:NVAX) released its quarterly earnings data on Monday, May, 9th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.33 by $0.77. The biopharmaceutical company had revenue of $703.97 million for the quarter, compared to the consensus estimate of $845.20 million. Novavax had a negative trailing twelve-month return on equity of 572.54% and a negative net margin of 93.91%. Novavax's revenue for the quarter was up 57.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($3.05) EPS.
View Novavax's earnings history.

Novavax's stock reverse split before market open on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split.

Novavax updated its FY 2022 earnings guidance on Monday, June, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $4.00 billion-$5.00 billion, compared to the consensus revenue estimate of $4.49 billion.

46 employees have rated Novavax CEO Stanley C. Erck on Glassdoor.com. Stanley C. Erck has an approval rating of 71% among Novavax's employees.

Some companies that are related to Novavax include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of NVAX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Palo Alto Networks (PANW), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE).

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Novavax's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.92%), State Street Corp (3.19%), Citigroup Inc. (0.00%), Jane Street Group LLC (0.00%), Coatue Management LLC (1.13%) and JPMorgan Chase & Co. (0.00%). Company insiders that own Novavax stock include David M Mott, Gary C Evans, Gregory M Glenn, Gregory M Glenn, James F Young, John A Herrmann III, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck.
View institutional ownership trends for Novavax.

NVAX stock was sold by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Capital World Investors, Jane Street Group LLC, PEAK6 Investments LLC, Graham Capital Management L.P., Simplex Trading LLC, First Trust Advisors LP, and Group One Trading L.P.. Company insiders that have sold Novavax company stock in the last two years include David M Mott, Gary C Evans, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, and Stanley C Erck.
View insider buying and selling activity for Novavax or view top insider-selling stocks.

NVAX stock was acquired by a variety of institutional investors in the last quarter, including Coatue Management LLC, State Street Corp, Bank of America Corp DE, Citigroup Inc., Goldman Sachs Group Inc., Capital Fund Management S.A., Qube Research & Technologies Ltd, and International Biotechnology Trust PLC.
View insider buying and selling activity for Novavax or or view top insider-buying stocks.

Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVAX stock can currently be purchased for approximately $52.68.

Novavax (NASDAQ:NVAX) has a market capitalization of $4.12 billion and generates $1.15 billion in revenue each year. The biopharmaceutical company earns $-1.74 billion in net income (profit) each year or ($17.680010) on an earnings per share basis.

Novavax employs 1,541 workers across the globe.

Novavax was founded in 1987.

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The official website for Novavax is www.novavax.com. The biopharmaceutical company can be reached via phone at (240) 268-2000, via email at [email protected], or via fax at 240-268-2100.